Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD9592 + rilvegostomig
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AZD9592 + rilvegostomig is an experimental combination drug comprising **AZD9592**, an antibody-drug conjugate that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition receptor (c-MET) with a bispecific antibody, conjugated to a topoisomerase 1 inhibitor (TOP1i) payload; and **rilvegostomig** (also known as AZD2936), a bispecific monoclonal antibody targeting PD-1 and TIGIT immune checkpoints. This combination is designed as a dual immunotherapeutic and targeted therapy approach for solid tumors, such as non-small cell lung cancer (NSCLC), combining direct cytotoxicity (from AZD9592) with immune checkpoint blockade (from rilvegostomig). Both agents are developed by AstraZeneca.
02
Targets
EGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on AZD9592 + rilvegostomig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD9592 + rilvegostomig.